MedrxMedrx Co., Ltd.4586東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP
It lost about ¥735 for every ¥100 of sales at the operating level. Revenue changed -50.3% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | — | —× | -50.3% | —× | — |
| 2022 | — | —× | -63.4% | —× | — |
| 2023 | — | —× | -54.1% | —× | — |
| 2024 | — | —× | -37.3% | —× | — |
| 2025 | — | —× | -42.3% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8 | 59 | 30 | 258 | 128 |
| Cost of revenue | 2 | 3 | 2 | 0 | 1 |
| Gross profit | 6 | 57 | 27 | 258 | 127 |
| SG&A | 1,067 | 1,156 | 961 | 1,051 | 1,069 |
| Operating income | -1,061 | -1,099 | -934 | -793 | -942 |
| Pretax income | -1,058 | -1,109 | -930 | -803 | -925 |
| Income tax | 1 | 2 | 3 | 4 | 12 |
| Net income attributable to owners | -1,060 | -1,111 | -933 | -807 | -937 |
| Operating margin | -12709.3% | -1847.3% | -3161.0% | -307.5% | -735.5% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥1.7B | ¥994M | ¥1.72B | ¥1.98B | ¥1.75B |
| Total assets | ¥2.11B | ¥1.4B | ¥2.05B | ¥2.28B | ¥2.16B |
| Net assets | ¥1.96B | ¥1.21B | ¥1.92B | ¥2.17B | ¥2.05B |
| Share capital | ¥7.8B | ¥227.2M | ¥847.5M | ¥580.9M | ¥450.9M |
| Property, plant and equipment | ¥270.4M | ¥226.3M | ¥181.5M | ¥123.7M | ¥192.2M |
| Investment securities | — | — | — | ¥31.2M | ¥130.9M |
| Current assets | ¥1.75B | ¥1.09B | ¥1.79B | ¥2.07B | ¥1.82B |
| Current liabilities | ¥125.8M | ¥158.1M | ¥100M | ¥105.6M | ¥77.3M |
| Total liabilities | ¥153.1M | ¥185.6M | ¥127.5M | ¥105.6M | ¥108.5M |
| Equity attributable to owners of parent | ¥1.9B | ¥1.14B | ¥1.85B | ¥2.11B | ¥1.91B |
| Retained earnings | -¥13.3B | -¥2.15B | -¥915.7M | -¥787.1M | -¥898.8M |
| Treasury stock | — | ¥0 | ¥0 | ¥0 | ¥0 |
EDINET (FSA Japan)
有価証券報告書－第24期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第23期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第22期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第21期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
有価証券報告書－第20期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
訂正有価証券報告書－第19期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 40 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.